X0306 4 2020-04-02 1 0001481512 Ra Pharmaceuticals, Inc. RARX 0001688199 Read Simon C/O RA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 Chief Scientific Officer Common Stock 2020-04-02 4 D 0 12595 48.00 D 0 D Stock Option (Right to Buy) 2.87 2020-04-02 4 D 0 46434 0 D 2026-06-16 Common Stock 46434 0 D Stock Option (Right to Buy) 2.87 2020-04-02 4 D 0 26422 0 D 2026-06-16 Common Stock 26422 0 D Stock Option (Right to Buy) 5.60 2020-04-02 4 D 0 25000 0 D 2026-08-16 Common Stock 25000 0 D Stock Option (Right to Buy) 16.64 2020-04-02 4 D 0 67500 0 D 2027-02-01 Common Stock 67500 0 D Stock Option (Right to Buy) 7.33 2020-04-02 4 D 0 55000 0 D 2028-02-02 Common Stock 55000 0 D Stock Option (Right to Buy) 21 2020-04-02 4 D 0 107000 0 D 2029-02-01 Common Stock 107000 0 D Restricted Stock Units 2020-04-02 4 D 0 9166 0 D Common Stock 9166 0 D Includes 6,361 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020. Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share. Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. /s/ David C. Lubner, Attorney-in Fact for Simon Read 2020-04-03